with the U.S. and Europe. The same report noted that the plans were not a certainty, and that a Shanghai listing was another possibility.She added that AstraZeneca has been operating in China for a decade and is its largest pharmaceutical company.
"China has actually been a great business for us," Sarin said, observing that the company's China branch had recorded four successive quarters of growth. "But what's really interesting about China is not just the commercial business, which is doing really well, but actually all the innovation that is coming out of China when we run our...global clinical studies. And a lot of the studies are also running in China," she said.
"There's also the ability to tap into local innovation. And it's not just us, even many of our peers have done licencing deals with really innovative biotech companies in China," she added. "So it's really not just commercial [interest], but being able to tap into that innovation."on Friday showed revenue growth ahead of estimates at 6% in the second quarter, following 1% growth in the first half. Core earnings per share rose by 25% to $2.15.
The company's China revenues expanded by 7%, slightly above the 6% recorded in Europe, but below the 10% growth in the U.S., including Covid-related figures.
Malaysia Malaysia Latest News, Malaysia Malaysia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: CNBC - 🏆 12. / 72 Read more »